{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:45:32Z","timestamp":1785851132420,"version":"3.56.0"},"reference-count":41,"publisher":"Universa BV","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Background: Hepatitis C is a viral infection caused by the hepatitis C virus (HCV) with people who inject drugs as the main group at risk worldwide.\n\nAim: This study investigated the differences in uptake for HCV screening and treatment between persons in opioid substitution therapy (OST) and the other members of the Christian Health Insurance Fund in Belgium.\n\nMethods: Invoice data were retrospectively collected from the Christian Health Insurance Fund, representing 42% of the healthcare users. Information on demographics, screening, diagnostic tests, treatment and disease progression was obtained from 2008 till 2013. All people in this study were aged 20-65 year. Persons in the OST group were identified as having at least one prescription reimbursed for methadone. This group was compared to the other members of the Insurance Fund not on OST (NOST).\n\nResults: The Insurance Fund registered 8,409 unique OST and 3,525,190 members in the general group. HCV RNA screening rate was higher in the OST group after correction for age and gender (4.3% vs. 0.2%). Ribavirin reimbursement, did not differ between the OST and NOST group screened for HCV RNA (16.9% vs. 14.4%), though the probability of having ribavirin reimbursed was smaller for females than for males. Procedures concerning disease progression were reimbursed less frequently in the HCV RNA screened OST group compared to the NOST group (0.3% vs. 1.2%).\n\nConclusion: People on OST were screened more often for HCV RNA. However, the general uptake for HCV screening and treatment in both populations remained suboptimal.<\/jats:p>","DOI":"10.51821\/84.2.311","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:01:40Z","timestamp":1627603300000},"page":"311-316","source":"Crossref","is-referenced-by-count":2,"title":["Uptake of hepatitis C virus screening and treatment in persons under opioid substitution therapy between 2008 and 2013 in Belgium"],"prefix":"10.51821","volume":"84","author":[{"given":"D","family":"Busschots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Arain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6.M.","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bruckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Rakhmawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Corten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Cornelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Mathei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Buntinx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Robaeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27062","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"LOZANO R, NAGHAVI M, FOREMAN K, LIM S, SHIBUYA K, ABOYANS V, et al. Global and regional mortality from 235 causes of death for  20  age  groups  in  1990  and  2010  :  a  systematic  analysis  for  the  Global  Burden of Disease Study 2010. Lancet. 2012, 380(9859) : 2095-128.","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"GOWER  E,  ESTES  C,  BLACH  S,  RAZAVI-SHEARER  K,  RAZAVI  H. Global  epidemiology  and  genotype  distribution  of  the  hepatitis  C  virus  infection. Journal of hepatology. 2014, 61(1 Suppl) : S45-57.","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"ref2","unstructured":"Global Hepatitis Report 2017. Geneva : World Health Organization, 2017."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"MATHEI  C,  ROBAEYS  G,  VAN  DAMME  P,  BUNTINX  F,  VERRANDO  R.  Prevalence  of  hepatitis  C  in  drug  users  in  Flanders  :  determinants  and  geographic differences. Epidemiology and infection. 2005, 133(1) : 127-36.","DOI":"10.1017\/s0950268804002973"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"BEUTELS M, VAN DAMME P, AELVOET W, DESMYTER J, DONDEYNE F,  GOILAV  C,  et  al.  Prevalence  of  hepatitis  A,  B  and  C  in  the  Flemish  population. European Journal of Epidemiology. 1997, 13(3) : 275-80.","DOI":"10.1023\/a:1007393405966"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"MICALESSI MI, GERARD C, AMEYE L, PLASSCHAERT S, BROCHIER B, VRANCKX R. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. Journal of Medical Virology. 2008, 80(4) : 640-5.","DOI":"10.1002\/jmv.21145"},{"key":"ref6","unstructured":"MUYLDERMANS G. VGS, VAN BAELEN L. Jaarrapport 2016 : hepatitis C virus : Wetenschappelijk Instituut Volksgezondheid - Institution Scientifique de sant\u00e9 Publique (WIV-ISP), 2016 [Available from : https:\/\/nrchm.wiv-isp.be\/nl\/ref_centra_labo\/hepatitis\/Rapporten\/Rapport%20HCV%202016.pdf."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"LITZROTH A, SUIN V, WYNDHAM-THOMAS C, QUOILIN S, MUYLDERMANS G, VANWOLLEGHEM T, et al. Low hepatitis C prevalence in Belgium : implications for treatment reimbursement and scale up. BMC Public Health. 2019, 19(1) : 39.","DOI":"10.1186\/s12889-018-6347-z"},{"key":"ref8","unstructured":"MATHEI C, BOURGEOIS S, BLACH S, BRIXKO C, MULKAY JP, RAZAVI  H,  et  al.  Mitigating the  burden  of  hepatitis  C  virus  among  people  who inject drugs in Belgium. Acta Gastroenterol. Belg. 2016, 79(2) : 227-32."},{"key":"ref9","unstructured":"WHO.  Guidelines  for  the  screening,  care  and  treatment  of  persons  with  chronic hepatitis C infection. Updated version, April 2016. 2016."},{"key":"ref10","unstructured":"Federale  Overheidsdienst  Volksgezondheid  VvdveL.  Belgisch  staatsblad-Moniteur Belge : Protocolakkoord \u2018HCV-plan\u2019. Brussels 2014. p. 57926-40."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"ALAVI M, RAFFA JD, DEANS GD, LAI C, KRAJDEN M, DORE GJ, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2014, 34(8) : 1198-206.","DOI":"10.1111\/liv.12370"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"MEHTA  SH,  GENBERG  BL,  ASTEMBORSKI  J,  KAVASERY  R,  KIRK  GD,  VLAHOV  D,  et  al.  Limited  uptake  of  hepatitis  C  treatment  among  injection drug users. Journal of community health. 2008, 33(3) : 126-33.","DOI":"10.1007\/s10900-007-9083-3"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"BENNETT H, MCEWAN P, SUGRUE D, KALSEKAR  A,  YUAN  Y. Assessing  the  Long-Term  Impact  of  Treating  Hepatitis  C  Virus  (HCV)-Infected  People Who  Inject  Drugs  in  the  UK  and  the  Relationship  between Treatment Uptake and Efficacy on Future Infections. PLoS One. 2015, 10(5) : e0125846.","DOI":"10.1371\/journal.pone.0125846"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"VAN  BAELEN  L,  ANTIONE  J,  DE  RIDDER  K,  MUYLDERMANS  G,  GREAMEAUX  L.  Diagnostic  Hepatitis  C  Testing  of  People  in  Treatment  for Substance Use Disorders in Belgium Between 2011 and 2014  : A Cross-Sectional Study. Acta Gastroenterologica Belgica. 2019, 82(1) : 35-42.","DOI":"10.1186\/s13690-018-0254-8"},{"key":"ref15","unstructured":"WHO. Global Hepatitis Report, 2017. Geneva, 2017."},{"key":"ref16","unstructured":"RIZIV. Antivirale geneesmiddelen tegen hepatitis C  : vergoedingsvoorwaarden vanaf  1  januari  2017  :  RIZIV,  2018  [Available  from  :  http:\/\/www.riziv.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/geneesmiddel-gezondheidsproduct\/terugbetalen\/specialiteiten\/wijzigingen\/Paginas\/antiretrovirale_hepatitisc_terugbetalingsvoorwaarden_20170101.aspx#.Ww0_40iFNPY."},{"key":"ref17","unstructured":"EMCDDA. European Drug Report 2015 : Trends and Developments. Lisbon, Portugal, 2015."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"DE  MAEYER  J,  VANDERPLASSCHEN  W,  BROEKAERT  E.  Quality  of  life  among  opiate-dependent  individuals  : A  review  of  the  literature.  Int.  J.  Drug Policy. 2010, 21(5) : 364-80.","DOI":"10.1016\/j.drugpo.2010.01.010"},{"key":"ref19","unstructured":"Federale Overheidsdienst B. Healthcare costs : belgium.be, 2016 [Available from : https:\/\/www.belgium.be\/en\/health\/healthcare_costs."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"BEDOSSA  P,  POYNARD  T.  An  algorithm  for  the  grading  of  activity  in  chronic  hepatitis  C. The  METAVIR  Cooperative  Study  Group.  Hepatology. 1996, 24(2) : 289-93.","DOI":"10.1002\/hep.510240201"},{"key":"ref21","unstructured":"MICHIELSEN P, BRENARD R, BOURGEOIS N, DE GALOCSY C, DELWAIDE  J,  HENRION  J,  et  al.  Hepatitis  C  :  screening,  treatment  and  prevention practical guidelines. Acta Gastroenterologica Belgica. 2003, 66(1) : 15-9."},{"key":"ref22","unstructured":"GERKENS  S  MN,  THIRY  N,  HULSTAERT  F.  Hepatitis  C  :  screening  and  prevention  :  Hepatitis  C  :  screening  en  preventie.  Belgian  Health  Care  Knowledge Center (KCE). 2012."},{"key":"ref23","unstructured":"LANTHIER N, RUIZ-MORENO A, DAHLQVIST G, DELIRE B, ST\u00c4RKEL P, HORSMANS Y. Results of a screening campaign for hepatitis C  viral  infection  in  a  Brussels  hospital    :  do  we  need  to  go  further?  Acta Gastroenterologica Belgica. 2019, 82(2) : 338."},{"key":"ref24","unstructured":"MUYLDERMANS G, BIELEN R, BOTTERMAN R, BOURGEOIS S,  COLLE  I,  DERESSA  B,  et  al.  Hepatitis  C  virus  (HCV)  prevalence  estimation in the adult general population in Belgium : a meta-analysis. Acta Gastroenterologica Belgica. 2019, 82(4) : 479-85."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"BIELEN R, KREMER C, KOC OM, BUSSCHOTS D, HENDRICKX DM,  VANELDEREN  P,  et  al.  Screening  for  hepatitis  C  at  the  emergency  department  :  Should  babyboomers  also  be  screened  in  Belgium?  Liver  Int. 2018.","DOI":"10.1111\/liv.14016"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"SCHILLIE S, WESTER C, OSBORNE M, WESOLOWSKI L, RYERSONN A. CDC recommendations for Hepatitis C screening among adults. MMWR Recomm Rep. 2020, 69(2) : 1-17.","DOI":"10.15585\/mmwr.rr6902a1"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"LAZARUS JV, SPERLE I, MATICIC M, WIESSING L. A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect. Dis. 2014, 14 Suppl 6 : S16.","DOI":"10.1186\/1471-2334-14-s6-s16"},{"key":"ref28","unstructured":"KEYMEULEN  H,  VAN  DE  VELD  H,  DEGROOTE  H,  GEERTS A,  VAN  VLIERBERGHE H, VERHELST X. Patients with chronic hepatitis C virus infection are at high risk of being lost to follow-up. Focused interventions can increase linkage to care. Acta Gastroenterologica Belgica. 2020, 83(1) : 94."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"GREBELY  J,  DORE  GJ.  What  is  killing  people  with  hepatitis  C  virus  infection? Seminars in liver disease. 2011, 31(4) : 331-9.","DOI":"10.1055\/s-0031-1297922"},{"key":"ref30","unstructured":"RIZIV. Antivirale geneesmiddelen tegen hepatitis C  : vergoedingsvoorwaarden vanaf 1 januari 2019. RIZIV, 2018"},{"key":"ref31","unstructured":"BOURGEOIS  S,  MULKAY  J,  LASSER  L,  ROBAEYS  G,  BASTENS  B,  DELWAIDE  J,  et  al.  A  multicentre,  observational  study  on  demographic  and disease characteristics of patients seeking care for chronic hepatitis C in Belgium in 2016. Acta Gastroenterologica Belgica. 2019, 82(1) : 43-52."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"CASTERA  L,  VERGNIOL  J,  FOUCHER  J,  LE  BAIL  B,  CHANTELOUP  E,  HAASER  M,  et  al.  Prospective  comparison  of  transient  elastography, Fibrotest, APRI,  and  liver  biopsy  for  the  assessment  of  fibrosis  in  chronic hepatitis C. Gastroenterology. 128, United States 2005. p. 343-50.","DOI":"10.1053\/j.gastro.2004.11.018"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"CASTERA  L,  FORNS  X,  ALBERTI  A.  Non-invasive  evaluation  of  liver fibrosis  using  transient  elastography.  Journal  of  hepatology.  2008,  48(5) : 835-47.","DOI":"10.1016\/j.jhep.2008.02.008"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"LIVER  EAFTSOT.  EASL  Clinical  Practice  Guidelines  :  management  of  hepatitis C virus infection. J. Hepatol. 2011, 55(2) : 245-64.","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"EUROPEAN ASSOCIATION FOR STUDY OF L. EASL Recommendations on Treatment of Hepatitis C 2015. Journal of hepatology. 2015, 63(1) : 199-236.","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"GREBELY J, ROBAEYS G, BRUGGMANN P, AGHEMO A, BACKMUND M,  BRUNEAU  J,  et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int. J. Drug Policy. 2015, 26(10) : 1028-38.","DOI":"10.1016\/j.drugpo.2015.07.005"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"ROOSE  RJ,  COCKERHAM-COLAS  L,  SOLOWAY  I,  BATCHELDER A,  LITWIN AH. Reducing barriers to hepatitis C treatment among drug users : an  integrated  hepatitis  C  peer  education  and  support  program.  Journal  of  health care for the poor and underserved. 2014, 25(2) : 652-62.","DOI":"10.1353\/hpu.2014.0096"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"MATHERS BM, DEGENHARDT L, BUCELLO C, LEMON J, WIESSING L,  HICKMAN  M.  Mortality  among  people  who  inject  drugs  :  a  systematic  review and meta-analysis. Bull. World Health Organ. 2013, 91(2) : 102-23.","DOI":"10.2471\/blt.12.108282"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"KIELLAND  KB,  SKAUG  K,  AMUNDSEN  EJ,  DALGARD  O.  All-cause  and liver-related mortality in hepatitis C infected drug users followed for 33 years : a controlled study. Journal of hepatology. 2013, 58(1) : 31-7.","DOI":"10.1016\/j.jhep.2012.08.024"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"AMIN  J,  LAW  MG,  BARTLETT  M,  KALDOR  JM,  DORE  GJ.  Causes  of  death  after  diagnosis  of  hepatitis  B  or  hepatitis  C  infection  :  a  large  community-based linkage study. Lancet. 2006, 368(9539) : 938-45.","DOI":"10.1016\/s0140-6736(06)69374-4"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T12:46:26Z","timestamp":1627649186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/1923\/Uptake%20of%20hepatitis%20C%20virus%20screening%20and%20treatment%20in%20persons%20under%20opioid%20substitution%20therapy%20between%202008%20and%202013%20in%20Belgium\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.51821\/84.2.311","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}